Related Experiment Video

Updated: Apr 11, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Association of the rs688 Polymorphism in the Gene Encoding Low-Density Lipoprotein Receptor in Bangladeshi Population

Imran Hossain1, Nahid Sharmin2, Istiaque Ahmed3

  • 1Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh, du.ac.bd.

Genetics Research
|April 10, 2026
PubMed

Insights

The TT genotype of the LDL receptor (LDLR) rs688 single-nucleotide polymorphism is linked to increased coronary artery disease (CAD) risk in Bangladeshi individuals. This genotype also correlates with higher low-density lipoprotein (LDL) cholesterol levels.

Area of Science:

  • Genetics and Cardiovascular Disease

Background:

  • Coronary artery disease (CAD) is a major global health concern, significantly driven by elevated low-density lipoprotein (LDL) cholesterol.
  • The LDL receptor (LDLR) is crucial for cholesterol homeostasis, regulating blood LDL levels.
  • The LDLR rs688 single-nucleotide polymorphism (SNP) may affect mRNA splicing, potentially influencing LDLR function and lipid metabolism.

Purpose of the Study:

  • To investigate the association between the LDLR rs688 polymorphism and susceptibility to CAD in the Bangladeshi population.
  • To determine the relationship between the LDLR rs688 polymorphism and serum LDL levels in CAD patients.

Main Methods:

  • A case-control study involving 150 CAD patients and 75 healthy controls.
  • Biochemical tests were used to measure lipid profiles (HDL, LDL, triglycerides, total cholesterol).
  • Allele-specific PCR (AS-PCR) was employed to identify LDLR genotypes.

Main Results:

  • The LDLR rs688 TT genotype was more frequent in the CAD group compared to controls (17.33% vs. 15.33%).
  • A significant association was found between the LDLR rs688 TT genotype and increased CAD risk (OR=3.617, p=0.0352).
  • Individuals with TT and CT genotypes had higher LDL levels than those with the CC genotype (p<0.05).
  • Multivariate logistic regression confirmed the independent association of the LDLR rs688 TT genotype with CAD (p<0.05).

Conclusions:

  • Preliminary evidence suggests the LDLR rs688 TT genotype is associated with CAD in the Bangladeshi population.
  • This genetic factor may contribute to altered LDL levels and CAD susceptibility.
  • Larger, population-based studies are needed for further validation.
Abstract

Keywords:
LDLR rs688coronary artery diseasegenotype frequencylipid profilesingle-nucleotide polymorphism

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
122
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
863
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
147